Related Experiment Videos
[Study of efficacy, safety and dosage on cefpodoxime proxetil in pediatric infections]
H Hirosawa1, Y Ishikawa, S Takahashi
1Department of Pediatrics, School of Medicine, Kyourin University.
Insights
Cefpodoxime proxetil (CPDX-PR) demonstrated 100% clinical efficacy in pediatric patients with various infections. This new cephalosporin antibiotic proved safe and effective for treating children, with no reported side effects.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Context:
- Cefpodoxime proxetil (CPDX-PR) is a novel cephalosporin antibiotic.
- Pediatric infectious diseases require effective and safe treatment options.
Purpose:
- To evaluate the efficacy and safety of Cefpodoxime proxetil in pediatric patients.
- To assess the clinical and bacteriological outcomes of CPDX-PR treatment.
Summary:
- A study involved 21 pediatric patients (3 months to 9 years) treated with oral Cefpodoxime proxetil.
- Dosages ranged from 4.4-5.8 mg/kg thrice daily for 3-12 days, treating conditions like pharyngitis, tonsillitis, and bronchitis.
- Clinical efficacy was 100% (18 excellent, 3 good responses), with a 90.9% bacteriological eradication rate. One case showed elevated liver enzymes (GOT/GPT), but no other side effects were noted.
Impact:
- Cefpodoxime proxetil shows significant promise as a safe and highly effective antibiotic for pediatric infectious diseases.
- The drug's excellent efficacy and safety profile support its consideration in pediatric treatment regimens.
Abstract:
Cefpodoxime proxetil (CS-807, CPDX-PR), a new cephalosporin antibiotic, was investigated for its usefulness in pediatrics. 1. The total number of patients treated were 21 with their ages ranging from 3 months to 9 years and 1 month, consisting of 5 male and 16 female infants. 2. Single dosages of the drug ranged between 4.4 mg and 5.8 mg/kg with oral administration for 3 times daily in fasting. A total aggregated dosage was between 46.4 mg/kg and 200.0 mg/kg. The length of administration was 3 to 12 days. 3. The breakdown of symptoms were 9 cases of acute pharyngitis, 5 cases of acute tonsillitis, 3 cases of acute bronchitis, and 1 case each of impetigo + purulent rhinitis, cervical lymphadenitis, scarlet fever, and urinary tract infection. 4. The clinical efficacy rate was 100% with 18 excellent responses and 3 good responses. 5. The bacteriological efficacy rate was 90.9% in eradication rate, based on results on 17 strains of suspected causative microorganism among which 10 strains were eradicated, 1 strain was decreased, and 6 strains were unknown. 6. There was no side effect during the treatment and after the discontinuation, while, in clinical laboratory tests, GOT and GPT were elevated in 1 case which was judged as abnormal. No patient refused the drug. CPDX-PR was considered to be very useful drug because of its excellent efficacy and safety in pediatrics in treating infectious diseases.